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Summary: Our model predicts that onchocerciasis can be eliminated using test-and-not-treat (TaNT) 
in L. loa co-endemic areas. The required treatment duration using TaNT would be only slightly longer 













Mass drug administration (MDA) with ivermectin is the main strategy for onchocerciasis elimination. 
Ivermectin is generally safe but associated with serious adverse events in individuals with high Loa 
loa microfilarial densities (MFD). Therefore, ivermectin MDA is not recommended in areas where 
onchocerciasis is hypo-endemic and L. loa is co-endemic. To eliminate onchocerciasis in those areas, 
a test-and-not-treat (TaNT) strategy has been proposed. We investigated whether onchocerciasis 
elimination can be achieved using TaNT and the required duration.  
Methods 
We used the individual-based model ONCHOSIM to predict the impact of TaNT on onchocerciasis 
microfilarial (mf) prevalence. We simulated pre-control mf prevalence levels from 2-40%. The impact 
of TaNT was simulated under varying levels of participation, systematic non-participation and 
exclusion from ivermectin due to high L. loa MFD. For each scenario, we assessed the time to 
elimination, defined as bringing onchocerciasis mf prevalence below 1.4%.  
Results 
In areas with 30-40% pre-control mf prevalence, the model predicted that it would take between 14 
and 16 years to bring the mf prevalence below 1.4% using conventional MDA, assuming 65% 
participation. TaNT would increase the time to elimination by up to 1.5 years, depending on the level 
of systematic non-participation and the exclusion rate. At lower exclusion rates (≤2.5%), the delay 
would be less than six months. 
Conclusions 
Our model predicts that onchocerciasis can be eliminated using TaNT in L. loa co-endemic areas. The 
required treatment duration using TaNT would be only slightly longer than in areas with conventional 
MDA, provided that participation is good.  












Mass drug administration (MDA) with ivermectin is the main strategy for the elimination of 
onchocerciasis. Although ivermectin is generally safe, the drug has been associated with serious 
adverse events (SAE) in persons with Loa loa,[1] a filarial parasite endemic in forest areas of Central 
Africa.[2] People with L. loa microfilarial densities (MFD) greater than 30,000 microfilariae per 
milliliter (mf/mL) of blood are at high risk of developing potentially fatal encephalopathy.[3, 4] Since 
the 1990s, more than 500 SAE cases with encephalopathy have been reported after treatment with 
ivermectin, of which 60 led to death.[4, 5] 
The World Health Organization (WHO)/Mectizan Donation Program guidelines approve ivermectin 
MDA in meso- and hyperendemic onchocerciasis areas (i.e. onchocercal nodule prevalence >20% in 
adults) with loiasis co-endemicity, if accompanied by enhanced surveillance for adverse events.[6] 
The potential benefits of MDA (e.g. prevention of blindness and onchodermatitis) were felt to 
outweigh the potential risk of Loa-related post-ivermectin SAEs and early supportive care of SAE 
cases could reduce the risk of mortality and long-term sequelae. However, there is no WHO-endorsed 
strategy for hypoendemic onchocerciasis areas with loiasis co-endemicity, which hinders 
onchocerciasis elimination. 
In order to eliminate onchocerciasis in those areas, a “test-and-not-treat” (TaNT) strategy has been 
proposed.[5] In a pilot study in Cameroon, the LoaScope (a mobile video microscope scope [7]) was 
used to rapidly identify individuals with a loiasis MFD of ≥ 20,000 mf/mL, who were then excluded 
from subsequent ivermectin treatment.[5] In this study, the risk threshold was lowered for safety 
reasons. The participation rate in health areas varied between 51.5% and 68.4% of the total 
population, which was considered acceptable given the history of post-ivermectin loiasis-related 
SAEs in 1999 (after which ivermectin distribution was interrupted in hypoendemic onchocerciasis 
areas). Overall, only 2.1% of the subjects tested with the LoaScope were excluded from ivermectin 
treatment due to high loiasis MFD. During the second TaNT campaign in 2017, this percentage 
dropped to 1.5%. Of the individuals treated with ivermectin in the first round, 99.97% remained 
below the risk threshold, indicating that those individuals could have been safely retreated without 
retesting.[8]  
While the TaNT strategy has been successfully piloted in Cameroon, it remains unclear whether 
elimination of onchocerciasis is possible using this strategy and how long the program would have to 
be continued. We address these questions by mathematical modelling. For this purpose, we used the 
individual-based model ONCHOSIM[9, 10], which has been used previously to predict the impact of 















ONCHOSIM is a stochastic individual-based model that simulates the transmission of onchocerciasis 
in a closed dynamic population of approximately 440 individuals (rural village).[13, 14] The model 
simulates life histories of human individuals and Onchocerca volvulus worms and mf within 
individual human hosts. Transmission of infection occurs through bites of blackflies whose intensity 
is represented by the annual biting rate. The probability that an individual is bitten by a blackfly is 
assumed to depend on age (exposure to blackfly increases linearly between the ages of zero and 20), 
sex (higher exposure in males), personal factors (e.g. attractiveness to blackflies), and seasonal biting 
variation of blackflies. At each bite, blackflies can transmit or pick up the infection. Only a small 
proportion of transmitted larvae will successfully develop into adult worms. Following insemination 
of females by male worms, mf are produced, which can be picked up by the blackfly. These mf 
develop in the blackfly into the infective stage (L3), which is modelled deterministically in the vector. 
Infection acquired from other villages is captured by the parameter called external force of infection. 
Our model did not account for an association between onchocerciasis and loiasis intensity within 
individuals, as evidence suggests that the association is weak and insufficient to explain very high 
loiasis MFD.[15] Table S1 provides information about the quantification of biological parameters.  
Pre-control setting 
We simulated hypoendemic pre-control O. volvulus mf prevalence between 2-40%, by varying 
setting-specific transmission parameters: the annual biting rate, the shape of the gamma distribution 
describing variation in exposure between individuals, and the level of external force of infection. 
Parameter values were sampled from a predefined parameter space, and were accepted when the 
resulting pre-control mf prevalence in the endemic equilibrium would fall into one of the bins: 2-5%, 
5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%. The model was run until we had 1,000 
parameter combinations for each bin. The sampled parameter space and the underlying distribution of 
the intensity of infection are provided in Figure S1 and S2. 
Treatment scenarios 
Test-and-not-treat strategy 
The modelled TaNT strategy includes annual testing with the LoaScope of individuals for high loiasis 
MFD, which is repeated during the entire period of the simulation. Individuals who tested negative, 
i.e. loiasis MFD <20,000 mf/mL, were provided ivermectin. In our model, treatment with ivermectin 
was assumed to kill 99% of O. volvulus mf within one month.[16]  
The probability of participation of individuals in TaNT rounds is determined by age, sex and a 
lifelong participation factor. Children under the age of five years and a proportion of women in the 
reproductive age (pregnant or lactating) are excluded from TaNT, because they are not eligible to 
receive ivermectin. The lifelong participation factor (score between 0 and 1) represents personal 
circumstances that makes an individual less (low score) or more likely (higher score) to participate.[9, 
10] Some individuals may never participate, because they are chronically ill or refuse treatment, and 










The participation rate is defined as the percentage of the total population that is tested per round. With 
lower participation rates, systematic non-participation would be more likely. To cover realistic 
scenarios, we defined seven participation scenarios varying both the participation rate (50%, 65% and 
80%) and the systematic non-participation (0%, 5%, and 10%) (Table S2). 
As a result of TaNT, an additional percentage of the individuals tested is excluded from ivermectin 
because of high loiasis MFD. On average 2.1% of those tested was excluded from ivermectin during 
the pilot TaNT campaign.[5] To capture possible heterogeneity across endemic areas, we varied the 
exclusion rate: 1%, 2.5%, 5%, 7.5% and 10%. Since loiasis MFD in individuals has been found to be 
stable over time, we assume that individuals with high loiasis MFD remain excluded from ivermectin 
during their whole lifetime.[17] TaNT exclusion is modeled similarly to systematic non-participation. 
In the main analysis, we assumed that the annual TaNT exclusion rate remains fixed. However, 
observations from the second TaNT round in Okola showed that the exclusion dropped from 2.1% to 
1.5% within 18-months.[8] In a sensitivity analysis, we explored the impact of a decreasing exclusion 
rate. To match the observed change, we assumed an exponential drop (rate: 0.22 per year) in the first 
10 TaNT rounds and no exclusion due to high loiasis MFD in the following rounds. 
Mass drug administration  
As a reference scenario, we explored the impact of conventional ivermectin MDA (i.e. without pre-
testing), in which no one was excluded from treatment because of loiasis. Ivermectin MDA is 
simulated by specifying the time and coverage of the treatment. In order to compare this scenario 
head-to-head with the TaNT scenarios, we simulated annual ivermectin MDA using the same 
participation rates and systematic non-participation as in the TaNT scenarios.  
Analysis 
For pre-control mf prevalence levels between 2-40%, we predicted the impact of TaNT in loiasis co-
endemic areas and the impact of annual ivermectin MDA (reference scenario) over a period of 25 
years. 
In our scenarios, we assume that treatment in the main village and neighboring villages are started 
simultaneously, resulting in a drop of the external force of infection over time. To estimate the decline 
in the external force of infection, we simulated a hyperendemic area with annual ivermectin MDA and 
used the modeled rate of decline in the force of infection as a proxy (Figure S3). 
For each treatment scenario, we assessed the time until elimination of onchocerciasis. As in previous 
studies, we defined elimination as reaching a modelled mf prevalence below 1.4% (i.e. operational 
threshold for treatment interruption followed by surveillance).[9, 18] We ran the model for 50 years 
and assessed the year in which the mf prevalence first fell below 1.4% per run. If the target was not 
met, we assumed a duration until elimination of 50 years (equals the simulated period). Per treatment 
scenario, we then calculated the mean required treatment duration per pre-control level. We only 
present the results over a period of 25 years. 
For each treatment scenario, we also assessed the annual probability of achieving elimination, which 











Our study follows to the modelling principles of the NTD Modelling Consortium for policy-relevant 
work (Table S3).[19] 
Results 
 
Figure 1 shows the trend in onchocerciasis mf prevalence of the upper end of the hypoendemic profile 
(30-40%), assuming 65% participation with 5% systematic non-participation. Using conventional 
ivermectin MDA, elimination of onchocerciasis could be achieved after an average of 15 years. 
Implementing the TaNT strategy, assuming 5 and 10% TaNT exclusion, prolongs the mean time until 
elimination by 0.7 and 1.4 years, respectively. 
The delay in achieving onchocerciasis elimination using a TaNT strategy compared to conventional 
ivermectin MDA depends on the pre-control onchocerciasis mf prevalence, participation rate, 
systematic non-participation, and TaNT exclusion (Figure 2). Areas with lower levels of pre-control 
mf prevalence, higher participation rates and lower proportions of systematic non-participation would 
reach elimination sooner compared to areas with higher prevalence, lower participation and higher 
systematic non-participation. Areas with a pre-control mf level above 25% would not reach 
elimination within 25 years if the participation rate were 50%. Elimination could be reached within 25 
and 15 years if 65% and 80% of the population participates, respectively. 
Table 1 summarizes the average time to elimination for all treatment scenarios. Higher pre-control mf 
levels increase the time to onchocerciasis elimination by 2 to 5-fold compared to 2-10% pre-control 
mf prevalence. A 65% and 50% participation would increase the time to elimination by 1.4-fold and 
>2-fold compared to 80% participation, respectively. The time to elimination increases with higher 
TaNT exclusion rates. This increase is larger for areas with high pre-control onchocerciasis mf 
prevalence levels and high levels of systematic non-participation. At an exclusion of 10%, the time to 
elimination increases by 1.7, 1.5 and 3 years at most, assuming a 80%, 65%, and 50% participation, 
respectively. At lower levels of TaNT exclusion (i.e. ≤2.5%), the delay to reach the assumed 
elimination threshold compared to ivermectin MDA varies between 0.0-0.4, 0.0-0.3 and 0.1-0.8 years, 
assuming a 80%, 65%, and 50% participation, respectively.  
The probability of achieving onchocerciasis elimination increases with TaNT rounds in areas with 30-
40% pre-control mf prevalence (Figure 3). Reaching elimination within 25 years is very likely if the 
participation is 80% or 65%, and very unlikely if the participation is 50%. Lower rates of systematic 
non-participation and TaNT exclusion would increase the probability of reaching the elimination 
threshold.  
When we assume that the TaNT exclusion rate decreases over time, the time to elimination would be 
0.6 and 1.3 years shorter (assuming an initial exclusion rate of 5% and 10%, respectively) compared 













This study suggests that onchocerciasis can be eliminated in L. loa co-endemic areas using a TaNT 
strategy provided that participation is good. In areas with 30-40% pre-control mf prevalence, it would 
normally take approximately 14 to 16 years to bring onchocerciasis mf prevalence below 1.4% using 
conventional ivermectin MDA assuming 65% participation. A TaNT strategy would increase the 
duration of reaching elimination by only 1.5 years if 10% of the population were excluded from 
ivermectin treatment. At lower exclusion rates (≤2.5%) the delay would be less than six months, 
which is very promising. The most challenging areas will be those that are in the upper end of the 
hypoendemic profile. In these areas, the delay is generally longer and therefore more TaNT rounds 
and a higher participation would be required.  
Our results support the notion that good participation with minimal systematic non-participation are 
essential to eliminate onchocerciasis.[11] This holds true for both conventional ivermectin MDA and 
TaNT. A 65% participation rate of the total population may be considered acceptable but increasing it 
to 80% would further shorten the duration of elimination programs, especially in areas with pre-
control onchocerciasis mf prevalences of ≥20%. If participation were as low as 50%, it is very 
unlikely that onchocerciasis would be eliminated within 25 years, especially if a large proportion of 
the population is systematically not treated (due to systematic non-particpation or TaNT exclusion). 
Reaching high participation for TaNT might be more difficult than for ivermectin MDA, because 
blood samples need to be taken during daytime hours due to the diurnal periodicity of L. loa mf in the 
peripheral blood, making TaNT less flexible logistically.[20] In the pilot TaNT campaign, the 
participation varied between 51.5% and 68.4% of the total population.[5] Low participation was 
believed to be the result of fear of SAEs based on past experiences with neurological SAEs and 
deaths. In the second round, participation was higher and varied between 60.5% and 78% of the total 
population.[8] Another TaNT campaign conducted in 2017-2018 in the neighboring Soa health district 
and involving local health personnel and community volunteers showed an overall participation of 
approximately 66% in rural settings.[21] Urban and semi-urban areas show consistently lower rates of 
participation.[5, 21] The rationale of getting tested for safe treatment might lead to higher willingness 
to participate in future rounds, which could further reduce the time until elimination. Involvement of 
local personnel and volunteers might add trust and participation. Also, health education strategies 
have been suggested to increase participation.[22] 
To reach the assumed elimination threshold, our main findings suggest that TaNT should be repeated 
for 14.5 to 17.4 years in areas with pre-control onchocerciasis mf levels 30-40% and 65% 
participation. In Okola (pre-control mf prevalence: 15.3-29.9%),[5] the time to elimination would 
range between 11.3 and 14.6 years assuming 65% participation and 2.5% exclusion. Although 
sustaining TaNT for a long period would create a burden on health care systems in terms of 
operational challenges and costs, it is encouraging that the present study predicts that TaNT would 
delay elimination by a maximum of only 1.5 years. Moreover, it is very likely that the proportion that 
needs to be excluded due to high loiasis MFD will decrease over time. If an optimistic decreasing rate 
of exclusion is assumed, this could reduce the time to elimination by up to 1.3 years (Figure 4). In 
order to reduce the operational challenges and cost of TaNT, testing only those who were not tested 
previously or were excluded due to high loiasis MFD should be considered. After several years, the 
number of individuals requiring testing would be small. Conventional MDA could be organized for 










requiring testing. Such an approach would further reduce the time to elimination and costs. Generally, 
the number of people who (after participating in TaNT) take ivermectin is crucial for onchocerciasis 
elimination. 
Alternative treatment strategies might be considered particularly in areas with higher pre-control 
onchocerciasis mf levels, because those areas would require more effort on the part of programs to 
ensure good participation rates and minimal systematic non-participation. Mass treatment with a drug 
that is effective for onchocerciasis and safe to use in people with high loiasis MFD would be 
programmatically preferred. For example, drugs that work by killing the Wolbachia symbiont of O. 
volvulus worms (not present in L. loa worms) or other macrofilaricidal only or both micro- and 
macrofilaricidal drugs could be considered. An example is doxycycline, which is known to have 
macrofilaricidal activity against O. volvulus but does not affect L. loa.[23, 24] Unfortunately, 
doxycycline is impractical to use on a large scale, because of the long regimen (4-6 weeks) and 
contra-indications in pregnant women and children under 12 years of age. Alternatively, a 
macrofilaricide could be provided only to individuals excluded from ivermectin due TaNT, and after 
testing for O. volvulus. Such an approach would lower the transmission intensity and would likely 
decrease the required time to elimination of onchocerciasis. This would only be practical if the 
percentage of exclusion were low. In order to further reduce the time to elimination, complementary 
vector control might be considered as an additional measure.[25]  
As in previous studies, we defined elimination as reaching a modelled mf prevalence below 1.4%. 
Whether the chosen threshold would lead to elimination of transmission strongly depends on pre-
control mf levels and local transmission conditions.[26] At lower transmission intensities, a low 
threshold may not be necessary to achieve elimination. In fact, elimination of transmission, defined as 
99% probability of elimination 50 years post-treatment, could be achieved after 5 to 6 years of 
treatment in hypoendemic settings, meaning that elimination could already be achieved at a higher mf 
prevalence threshold than the suggested 1.4% (Figure S4). This threshold also depends on the 
assumed level exposure heterogeneity. When a lower level of exposure heterogeneity is assumed, 
elimination could be achieved sooner. The 1.4% threshold used in this study can be regarded as 
conservative, and it is very likely that elimination of transmission would be achieved when this 
threshold is reached.  
In reality, the infection dynamics will be influenced by movement of infected humans or flies, as well 
as changes in demographic, geographic, and environmental conditions. To account for movement of 
infected humans or flies, our model includes an external force of infection representing incoming 
infections from neighboring areas. The level of control in neighboring areas is an important 
determinant for the success and duration of elimination programs in a certain village. If treatment (e.g. 
ivermectin MDA) in neighboring areas occurred earlier, time to elimination would drop by 4 to 6 
years (Figure S5). Moreover, if we assume no incoming infections from neighboring villages, 
elimination could be achieved without intervention in some situations.  
Conclusions 
Our model predicts that onchocerciasis can be eliminated using TaNT in hypoendemic areas co-
endemic for L. loa. Assuming good participation, the required duration of TaNT to reach a threshold 
of 1.4% mf prevalence would be only slightly longer than in areas with conventional ivermectin 
MDA. It will be most challenging to achieve elimination in areas that are in the upper end of the 
hypoendemic profile. In such areas, elimination could take more than 15 years depending on 
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 None 3.6 7.5 9.1 10.0 4.9 10.5 13.0 14.3 7.1 17.8 >25.0 >25.0 
  TaNT
c
 1.0% 3.6 7.7 9.2 10.2 4.9 10.6 13.1 14.5 7.2 18.0 >25.0 >25.0 
   2.5% 3.7 7.8 9.4 10.5 5.0 10.7 13.3 14.6 7.2 18.1 >25.0 >25.0 
   5.0% 3.9 8.1 9.8 10.9 5.2 11.0 13.6 15.0 7.4 18.4 >25.0 >25.0 
   7.5% 4.0 8.4 10.2 11.4 5.4 11.2 13.9 15.3 7.6 18.8 >25.0 >25.0 
   10.0% 4.2 8.7 10.6 11.7 5.5 11.4 14.2 15.6 7.7 19.3 >25.0 >25.0 
5% MDA
b




    
5.0 10.8 13.6 15.1 7.2 18.6 >25.0 >25.0 
   2.5% 
    
5.1 11.0 13.8 15.3 7.3 18.7 >25.0 >25.0 
   5.0% 
    
5.3 11.3 14.1 15.7 7.5 19.3 >25.0 >25.0 
   7.5% 
    
5.4 11.5 14.4 16.0 7.6 19.6 >25.0 >25.0 
   10.0%         5.5 11.7 14.8 16.4 7.8 19.9 >25.0 >25.0 
10% MDA
b




    
5.1 11.2 14.3 16.0 7.3 19.2 >25.0 >25.0 
   2.5% 
    
5.2 11.4 14.5 16.3 7.4 19.5 >25.0 >25.0 
   5.0% 
    
5.3 11.6 14.9 16.6 7.5 19.9 >25.0 >25.0 
   7.5% 
    
5.4 11.8 15.2 17.1 7.7 20.0 >25.0 >25.0 
   10.0%         5.6 12.1 15.6 17.4 7.8 20.7 >25.0 >25.0 
a Mean duration to reach the elimination threshold per pre-control bin; The colors indicate the duration: gradient 
from green (short duration) to red (long duration); b Ivermectin mass drug administration without pre-testing, i.e. 














Figure 1. Trends of onchocerciasis mf prevalence in a setting with 30-40% pre-control mf 
prevalence assuming 65% participation with 5% systematic non-participation. The mf 
prevalence was calculated every year before the start of a test-and-not-treat (TaNT) round. Any 
changes within a year are not shown. Panel A presents the results of individuals runs, showing the 
variation between those runs. Panel B shows the mean mf prevalence for all runs. The black line 
represents the reference scenarios, i.e. ivermectin MDA without pre-testing. The red and blue lines 
represent the TaNT strategy assuming 5 and 10% exclusion due to high L. loa MFD, respectively. We 
assume that TaNT is continued during the entire simulation period. The dashed line depicts the 
elimination threshold of 1.4% mf prevalence.  
Figure 2. Average time needed to reach an onchocerciasis mf prevalence below 1.4% by pre-
control level. The black line represents the reference scenarios, i.e. ivermectin MDA without pre-
testing. The red and blue lines represent TaNT assuming 5 and 10% exclusion due to high L. loa 
MFD, respectively. Each panel shows results under varying assumptions of participation (i.e. 80%, 
65%, and 50%) and systematic non-participation (i.e. 0%, 5%, and 10%). 
Figure 3. Probability of reaching an onchocerciasis mf prevalence below 1.4% in a setting with 
30-40% pre-control mf prevalence. The black line represents the reference scenarios, i.e. ivermectin 
MDA without pre-testing. The red and blue lines represent TaNT assuming 5 and 10% exclusion due 
to high L. loa MFD, respectively. Each panel shows results under varying assumptions of 
participation (i.e. 80%, 65%, and 50%) and systematic non-participation (i.e. 0%, 5%, and 10%). 
Figure 4. Trend of onchocerciasis mf prevalence in a setting with 30-40% pre-control mf 
prevalence assuming a fixed versus a decreasing annual exclusion percentage. The solid line 
represents the scenario assuming a fixed annual exclusion rate due to high L. loa MFD during all 
treatment rounds. The dotted line represents the scenario assuming an exponentially drop in the 
annual exclusion with a rate of 0.22 per year in the first 10 years, followed by no exclusion 
afterwards. The red and blue colored lines represent TaNT assuming an initial exclusion rate of 5 and 
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